Shihong Ma

Shihong Ma

Auto-generated profile, based on publicly available information

Shihong Ma

Department of Obstetrics and Gynecology, UT Health San Antonio, San Antonio, Texas

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 August 2022 in Cancer Research
Verified
Journal Article
Closed access
PDF file
KAKristin A. Altwegg
Kristin A. Altwegg
SVSuryavathi Viswanadhapalli
Suryavathi Viswanadhapalli
MMMonica Mann
Monica Mann
Dimple ChakravartyDimple Chakravarty
Dimple Chakravarty
SKSamaya Krishnan
Samaya Krishnan
RVRatna Vadlamudi
Ratna Vadlamudi
Most patients with estrogen receptor alpha–positive (ER+) breast cancers initially respond to treatment but eventually develop therapy resistance with disease progression. Overexpression of oncogenic ER coregulators, including proline, glutamic acid, and leucine-rich protein 1 (PELP1), are implicated in breast cancer progression. The lack of small molecules that inhibits PELP1 represents a major knowledge gap. Here, using a yeast-two-hybrid screen, we identified novel peptide inhibitors of PELP1 (PIP). Biochemical assays demonstrated that one of these peptides, PIP1, directly interacted with PELP1 to block PELP1 oncogenic functions. Computational modeling of PIP1 revealed key residues contributing to its activity and facilitated the development of a small-molecule inhibitor of PELP1, SMIP34, and further analyses confirmed that SMIP34 directly bound to PELP1. In breast cancer cells, SMIP34 reduced cell growth in a dose-dependent manner. SMIP34 inhibited proliferation of not only wild-type (WT) but also mutant (MT) ER+ and therapy-resistant breast cancer cells, in part by inducing PELP1 degradation via the proteasome pathway. RNA sequencing analyses showed that SMIP34 treatment altered the expression of genes associated with estrogen response, cell cycle, and apoptosis pathways. In cell line–derived and patient-derived xenografts of both WT and MT ER+ breast cancer models, SMIP34 reduced proliferation and significantly suppressed tumor progression. Collectively, these results demonstrate SMIP34 as a first-in-class inhibitor of oncogenic PELP1 signaling in advanced breast cancer. Significance: Development of a novel inhibitor of oncogenic PELP1 provides potential therapeutic avenues for treating therapy-resistant, advanced ER+ breast cancer.

1 July 2021 in Molecular Immunology
Verified
Journal Article
Closed access
LLLu Lu
Lu Lu
ZLZhuohang Li
Zhuohang Li
CSChengying Shan
Chengying Shan
SMShihong Ma
Shihong Ma
WNWei Nie
Wei Nie
SCShu Chengjie
Shu Chengjie

14 February 2020 in Cancer Research
Verified
Conference Paper
Closed access
RVRatna Vadlamudi
Ratna Vadlamudi
SVSuryavathi Viswanadhapalli
Suryavathi Viswanadhapalli
XLXihui Liu
Xihui Liu
Taekyung LeeTaekyung Lee
Taekyung Lee
GSGangadhara R Sareddy
Gangadhara R Sareddy
GRGanesh V. Raj
Ganesh V. Raj
Background: A significant proportion of breast cancers (BC) that express estrogen receptor α (ERα) will initially respond to antiestrogens or aromatase inhibitors. However, endocrine therapy resistance is common with progression to incurable metastases. A significant proportion (~39%) of therapy resistant tumors acquires ERα mutations which enables estrogen-independent constitutive interaction of ERα with coregulators, transcription and resistance to endocrine therapy. Drugs that specifically target and block mutant-ERα (MT ER)-coregulator driven signaling are urgently needed to treat therapy-resistant BC. Methods: Using an innovative strategy of oligobenzamide-based peptidomimetics (small synthetic organic molecules), we developed an estrogen receptor modulator ERX-41 that disrupt the interactions between MT ERα and critical coregulators. Effect of ERX-41 was evaluated using BC models that express wild type (WT) ERα (MCF-7, ZR-75) and BC models with acquired resistance (MCF-7-TamR, MCF-7-LTLT), and engineered models that express ERα mutations (MCF-7-MT ERα-D538G, MCF-7-MT ERα-Y537S, ZR-75-MT ERα-D538G, ZR-75-MT ERα-Y537S). Mechanistic studies were performed using RNA-Seq, Mass spectrometry, immunoprecipitation, Western blotting, RT-qPCR and reporter gene assays. The in vivo efficacy of ERX-41 was examined using xenograft, and patient-derived explant (PDEX) models. Results: ERX-41 exhibited broad and potent activity (IC50 between 50-125 nM) against both WT and MT ERα driven BC models in in vitro assays. ERX-41 had no activity against benign breast epithelial cells. Mechanistic studies confirmed that ERX-41 modulates multiple ERα functions including alterations in ERα transcription, down regulation of ERα and ERα-signaling. Using immunoprecipitation mass spectrometry (IPMS) analyses, we found that ERX-41 disrupts the interaction of ERα with a number of protein binding partners. RNA-Seq analyses of ERX-41 treated BC cells indicated upregulation of endoplasmic reticulum stress pathways. Furthermore, mechanistic studies confirmed that anti-proliferative effect of ERX-41 is directly related to its ability to induce endoplasmic reticulum stress and subsequent unfolded protein response. Treatment of ERX-41 decreased the proliferation (Ki-67 staining) and increased apoptosis (TUNEL staining) in PDEX models. ERX-41 showed potent activity against WT ERαand MTERα xenograft models but no effect on mouse liver or body weight. Histologic evaluation of these tumors showed dramatically decreased Ki-67 proliferation indices. Conclusions: Collectively, our data indicate that ERX-41 could effectively target both the WT and MT ERα driven signaling and could be clinically translated for the treatment of therapy-resistant BC. Supported by NIH grant CA223828. Citation Format: Ratna Vadlamudi, Suryavathi Viswanadhapalli, Xihui Liu, Tae-Kyung Lee, Gangadhara R Sareddy, Shihong Ma, Mengxing Li, Ben Ho Park, Rajeshwar R Tekmal, Jung-Mo Ahn, Ganesh V. Raj. ERX-41, a novel drug to target and block mutant-ERα-coregulator driven signaling [abstract]. In: Proceedings of the 2019 San Antonio Breast Cancer Symposium; 2019 Dec 10-14; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2020;80(4 Suppl):Abstract nr P6-04-05.

31 March 2023
Verified
Other
Open access
KAKristin A. Altwegg
Kristin A. Altwegg
SVSuryavathi Viswanadhapalli
Suryavathi Viswanadhapalli
MMMonica Mann
Monica Mann
Dimple ChakravartyDimple Chakravarty
Dimple Chakravarty
SKSamaya Krishnan
Samaya Krishnan
RVRatna Vadlamudi
Ratna Vadlamudi
Most patients with estrogen receptor alpha–positive (ER+) breast cancers initially respond to treatment but eventually develop therapy resistance with disease progression. Overexpression of oncogenic ER coregulators, including proline, glutamic acid, and leucine-rich protein 1 (PELP1), are implicated in breast cancer progression. The lack of small molecules that inhibits PELP1 represents a major knowledge gap. Here, using a yeast-two-hybrid screen, we identified novel peptide inhibitors of PELP1 (PIP). Biochemical assays demonstrated that one of these peptides, PIP1, directly interacted with PELP1 to block PELP1 oncogenic functions. Computational modeling of PIP1 revealed key residues contributing to its activity and facilitated the development of a small-molecule inhibitor of PELP1, SMIP34, and further analyses confirmed that SMIP34 directly bound to PELP1. In breast cancer cells, SMIP34 reduced cell growth in a dose-dependent manner. SMIP34 inhibited proliferation of not only wild-type (WT) but also mutant (MT) ER+ and therapy-resistant breast cancer cells, in part by inducing PELP1 degradation via the proteasome pathway. RNA sequencing analyses showed that SMIP34 treatment altered the expression of genes associated with estrogen response, cell cycle, and apoptosis pathways. In cell line–derived and patient-derived xenografts of both WT and MT ER+ breast cancer models, SMIP34 reduced proliferation and significantly suppressed tumor progression. Collectively, these results demonstrate SMIP34 as a first-in-class inhibitor of oncogenic PELP1 signaling in advanced breast cancer.Significance:Development of a novel inhibitor of oncogenic PELP1 provides potential therapeutic avenues for treating therapy-resistant, advanced ER+ breast cancer.

31 March 2023
Verified
Other
Open access
KAKristin A. Altwegg
Kristin A. Altwegg
SVSuryavathi Viswanadhapalli
Suryavathi Viswanadhapalli
MMMonica Mann
Monica Mann
Dimple ChakravartyDimple Chakravarty
Dimple Chakravarty
SKSamaya Krishnan
Samaya Krishnan
RVRatna Vadlamudi
Ratna Vadlamudi
Supplementary Data from A First-in-Class Inhibitor of ER Coregulator PELP1 Targets ER+ Breast Cancer

31 March 2023
Verified
Other
Open access
KAKristin A. Altwegg
Kristin A. Altwegg
SVSuryavathi Viswanadhapalli
Suryavathi Viswanadhapalli
MMMonica Mann
Monica Mann
Dimple ChakravartyDimple Chakravarty
Dimple Chakravarty
SKSamaya Krishnan
Samaya Krishnan
RVRatna Vadlamudi
Ratna Vadlamudi
Supplementary Figure from A First-in-Class Inhibitor of ER Coregulator PELP1 Targets ER+ Breast Cancer